Enterin, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.enterininc.com
Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Orally Administered ENT-01 for Parkinson's Disease-Related Constipation Follow-on Safety "Roll-over" Study (Rollover)
- Conditions
- Parkinson DiseaseConstipation
- Interventions
- Drug: Active Investigational Treatment ENT-01
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Enterin Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT04483479
- Locations
- 🇺🇸
The Parkinson's and Movement Disorder Institute, Fountain Valley, California, United States
🇺🇸SC3 Research - Pasadena, Pasadena, California, United States
🇺🇸Rocky Mountain Movement Disorders Center, Englewood, Colorado, United States
A Study to Evaluate ENT-01 for the Treatment of Parkinson's Disease Dementia
- Conditions
- Parkinson DiseaseDementia
- Interventions
- Drug: Active Investigational Treatment ENT-01
- First Posted Date
- 2019-05-06
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Enterin Inc.
- Registration Number
- NCT03938922
- Locations
- 🇺🇸
Neuro Pain Medical Center, Fresno, California, United States
🇺🇸Evolution Research Group - Neuroscience Research Institution, Toms River, New Jersey, United States
🇺🇸Elias Research - Neurology Diagnostics Research, Dayton, Ohio, United States
Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET)
- Conditions
- Parkinson DiseaseConstipation
- Interventions
- Drug: Placebo TreatmentDrug: Active Investigational Treatment ENT-01
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Enterin Inc.
- Target Recruit Count
- 151
- Registration Number
- NCT03781791
- Locations
- 🇺🇸
Banner Sun Health Research Institute, Sun City, Arizona, United States
🇺🇸Clinical Trials, Inc., Little Rock, Arkansas, United States
🇺🇸The Parkinson's and Movement Disorder Institute, Fountain Valley, California, United States
Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation
- First Posted Date
- 2017-02-09
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Enterin Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT03047629
- Locations
- 🇺🇸
Keck Hospital of University of Southern California, Los Angeles, California, United States
🇺🇸Rocky Mountain Movement Disorders Center, PC, Englewood, Colorado, United States
🇺🇸Georgetown Universtiy, Department of Neurology, Washington, District of Columbia, United States